News Novartis bullish about future despite Gleevec pain The patent loss of its biggest earning drug has hit Novartis’ revenues, which fell 1% in the third quarter, while operating income declining 3 per cent.
Digital The TechBio way: Brendan Frey talks genomics, AI, and RNA pharmaphorum speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face